Phillip L. Campbell
- Urology top 1%
- Urinary Bladder and Prostate Research 4
- Immunology top 5%
- Mast cells and histamine 5
- Immunotherapy and Immune Responses 4
- Immunology and Allergy top 5%
- Cell Adhesion Molecules Research 10
- Rheumatology top 2%
- Systemic Lupus Erythematosus Research 5
- Genetics top 5%
-
- Chemokine receptors and signaling 7
-
- Systemic Sclerosis and Related Diseases 7
-
- Angiogenesis and VEGF in Cancer 4
- Co-authors
- Alisa E. KochM. Asif AminJeffrey H. RuthDavid A. FoxPei‐Suen TsouRobert B. NadlerDinesh KhannaElior Peles
- Journals
- Cell (1 paper)Proceedings of the National Academy of Sciences (2 papers)Journal of Clinical Oncology (1 paper)
- Partner nations
- United StatesAustraliaUnited Kingdom
In The Last Decade
Phillip L. Campbell
52 papers receiving 2.5k citations
Hit Papers
Peers
Comparison fields: 5 of 120
- Urology 285
- Immunology 647
- Immunology and Allergy 175
- Rheumatology 408
- Genetics 285
Countries citing papers authored by Phillip L. Campbell
This map shows the geographic impact of Phillip L. Campbell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Phillip L. Campbell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Phillip L. Campbell more than expected).
Fields of papers citing papers by Phillip L. Campbell
This network shows the impact of papers produced by Phillip L. Campbell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Phillip L. Campbell. The network helps show where Phillip L. Campbell may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Phillip L. Campbell, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 6 | |
| 2 | 2023 | 2 | |
| 3 | 2022 | 12 | |
| 4 | 2022 | 3 | |
| 5 | 2021 | 34 | |
| 6 | 2021 | 8 | |
| 7 | ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemiabreakdown → | 2020 | 252 |
| 8 | 2020 | 20 | |
| 9 | 2018 | 43 | |
| 10 | 2016 | 7 | |
| 11 | 2015 | 22 | |
| 12 | 2014 | 33 | |
| 13 | 2012 | 23 | |
| 14 | 2009 | 50 | |
| 15 | 2007 | 77 | |
| 16 | 2002 | 31 | |
| 17 | 2000 | 56 | |
| 18 | 2000 | 42 | |
| 19 | 2000 | 171 | |
| 20 | 1986 | 14 |
About Phillip L. Campbell
Phillip L. Campbell is a scholar working on Immunology and Allergy, Biological Psychiatry and Immunology, having authored 52 papers that have together received 2.5k indexed citations. Recurring topics across this work include Cell Adhesion Molecules Research (10 papers), Chemokine receptors and signaling (7 papers), Systemic Sclerosis and Related Diseases (7 papers), Systemic Lupus Erythematosus Research (5 papers), Mast cells and histamine (5 papers), Immunotherapy and Immune Responses (4 papers), Angiogenesis and VEGF in Cancer (4 papers) and Urinary Bladder and Prostate Research (4 papers). The work is most often cited by research in Urology (285 citations), Immunology (647 citations) and Immunology and Allergy (175 citations). Phillip L. Campbell has collaborated with scholars based in United States, Australia and United Kingdom. Frequent co-authors include Alisa E. Koch, M. Asif Amin, Jeffrey H. Ruth, David A. Fox, Pei‐Suen Tsou, Robert B. Nadler, Dinesh Khanna, Elior Peles, Ricardo Martínez and Gregory D. Plowman. Their work appears in journals such as Cell, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.